文献速递胸部肿瘤放疗放疗物理与技术

加拿大安大略省Ⅰ期非小细胞肺癌的管理:2010至2019年治疗模式与立体定向消融放疗利用的基于人群研究

The management of stage I Non-Small cell lung cancer (NSCLC) in Ontario: A Population-Based study of patterns of care and Stereotactic Ablative Body radiotherapy (SABR) utilization from 2010 to 2019.
PubMed 文献 · Radiother Oncol · 2024-02-15

该回顾性基于人群队列研究链接安大略省放疗电子记录与癌症登记数据库,纳入2010至2019年12,065例经活检证实的Ⅰ期非小细胞肺癌患者。61.7%接受手术,17.9%接受立体定向消融放疗(SABR),8.6%接受非SABR根治性放疗,11.7%仅观察。SABR使用率从7.5%升至24.4%,手术使用率从63.8%降至49.9%,全队列2年癌症特异性生存率从81.9%升至85.0%,但SABR、非SABR根治性放疗和观察组生存保持稳定。

要点

  • 2010至2019年安大略省Ⅰ期非小细胞肺癌SABR使用率从7.5%升至24.4%(p<0.0001)。
  • 手术使用率从63.8%降至49.9%(p<0.0001),全队列2年癌症特异性生存率从81.9%升至85.0%(p<0.0001)。
  • SABR、非SABR根治性放疗和观察组2年癌症特异性生存率保持稳定,手术组从92.1%升至95.7%(p<0.001)。

核心结论

  • 2010至2019年安大略省Ⅰ期非小细胞肺癌SABR使用增加、手术使用减少,全队列2年癌症特异性生存率从81.9%升至85.0%(p<0.0001)。
  • 各卫生区域间治疗模式存在显著差异,提示许多辖区需要改善SABR可及性的策略。

研究设计与样本

  • 回顾性基于人群队列研究,通过链接放疗电子记录与基于人群的癌症登记数据库开展。
  • 纳入2010至2019年加拿大安大略省经活检证实的Ⅰ期非小细胞肺癌患者,共12,065例。

主要发现

  • 全队列中61.7%接受手术,17.9%接受SABR,8.6%接受非SABR根治性放疗,11.7%仅观察。
  • 2010至2019年手术使用率从63.8%降至49.9%(p<0.0001),SABR使用率从7.5%升至24.4%(p<0.0001)。
  • 非SABR根治性放疗使用率从6.7%升至9.6%(p<0.0014),观察患者比例从14.4%降至12.0%(p<0.0001)。
  • 全队列2年癌症特异性生存率从81.9%升至85.0%(p<0.0001);手术组从92.1%升至95.7%(p<0.001)。
  • 接受SABR、非SABR根治性放疗和观察的患者生存保持稳定。

关键数值与推荐

  • SABR是医学上不可手术的Ⅰ期非小细胞肺癌患者的标准治疗。
  • 安大略省各卫生区域间治疗模式存在显著差异。

临床怎么用

  • 原文建议需要制定策略以改善许多辖区SABR的可及性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic Ablative Body Radiotherapy (SABR) is the standard of care for medically inoperable patients with Stage I NSCLC. The adoption of SABR and its association with cancer outcomes requires characterization. AIM: We described the management of biopsy-proven Stage I NSCLC with SABR, surgery, non-SABR curative radiotherapy (RT) and observation in Ontario, Canada, between 2010 and 2019. Temporal and geographic trends in practice and survival outcomes were analyzed. METHODS: This was a retrospective population-based cohort study conducted by linking electronic radiotherapy (RT) records to a population-based cancer registry. RESULTS: A total of 12,065 patients were identified, 61.7 % underwent surgery, 17.9 % received SABR, 8.6 % received non-SABR curative RT and 11.7 % were observed. Between 2010 and 2019, the utilization of surgery decreased (63.8 % to 49.9 %, p < 0.0001), while SABR use increased (7.5 % to 24.4 %, p < 0.0001), non-SABR curative RT use increased (6.7 % to 9.6 %, p < 0.0014) and patients observed decreased (14.4 % to 12.0 %, p < 0.0001). Substantial variation in practice exists across Ontario. Two- yr CSS improved for the entire cohort (81.9 % to 85.0 %, p < 0.0001). While there was improvement in 2 yr CSS for surgical patients (92.1 %% to 95.7 %, p < 0.001), survival for patients who received SABR, Non-SABR curative RT and observation remained stable. CONCLUSION: There has been an increase in SABR utilization and a reduction in surgical utilization with a corresponding increased survival of stage I patients in Ontario between 2010 and 2019. Substantial differences in practice patterns exist across health regions, suggesting the need for strategies to improve access to SABR in many jurisdictions.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ashworth A, Kong W, Owen T, et al. The management of stage I Non-Small cell lung cancer (NSCLC) in Ontario: A Population-Based study of patterns of care and Stereotactic Ablative Body radiotherapy (SABR) utilization from 2010 to 2019. Radiother Oncol. 2024. PMID: 38364940. doi:10.1016/j.radonc.2024.110153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。